Pluri (PLUR) Cash per Single Share

Symbol and logo of brand Pluristem Therapeutics (PLUR)

Pluri Inc. is developing innovative placental cell expansion methods for tissue regeneration. The rise in share prices confirms the success of automated 3D bioreactors, which eliminate human error. High R&D expenditures and strict FDA regulations create insurmountable barriers to entry for competitors. Cash per share currently demonstrates liquidity, with the latest value recorded as 0.55.

PLUR (Pluri Inc.) Cash Funds per Share history from 04/28/2023 to 11/20/2026

Analytical breakdowns for Pluri Inc.

- market value and analyst target forecast:
- cash and cash flow data:
Summary company analysis:Pluri Inc.
Core merchandise of Pluri Inc.

Pluri Inc. is developing the high-tech sector of 3D cell culturing and therapy licensing. By analyzing cash-per-share trends, an investor can see the actual volume of liquidity attributable to a single security. This metric is calculated as the ratio of available cash to the number of shares, eliminating market noise. An increase in this indicator confirms financial autonomy but may signal investment stagnation. This determines the fundamental stability of the business.